Hugel Inc 145020
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 145020 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- —
- Day Range
- KRW 208,500.00–231,000.00
- 52-Week Range
- —–—
- Bid/Ask
- KRW 211,500.00 / KRW 212,000.00
- Market Cap
- KRW 2.38 Tril
- Volume/Avg
- 79,430 / 59,060
Key Statistics
- Price/Earnings (Normalized)
- 23.14
- Price/Sales
- 8.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 4.92%
Company Profile
Hugel Inc is a biopharmaceutical company. It is in the business of manufacturing of biopharmaceuticals. The company's primary products are Botulinum toxin, Hyaluronic acid filler, and Cosmetics. It develops and promotes its products under the brand name of Wellage. The firm has manufacturing facilities in Shinbuk and Geodu.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 569
- Website
- http://www.hugel.co.kr
Comparables
Valuation
|
Metric
|
145020
|
085660
|
052020
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.14 | — | — |
Price/Book Value | 3.34 | 3.47 | 8.97 |
Price/Sales | 8.43 | 1.08 | 53.03 |
Price/Cash Flow | 22.52 | 36.86 | — |
Price/Earnings
145020
085660
052020
Financial Strength
|
Metric
|
145020
|
085660
|
052020
|
|---|---|---|---|
Quick Ratio | 9.25 | 0.73 | 8.87 |
Current Ratio | 9.89 | 0.83 | 9.33 |
Interest Coverage | 40.40 | 0.67 | −270.58 |
Quick Ratio
145020
085660
052020
Profitability
|
Metric
|
145020
|
085660
|
052020
|
|---|---|---|---|
Return on Assets (Normalized) | 11.26% | −0.51% | −43.51% |
Return on Equity (Normalized) | 14.79% | −2.90% | −54.60% |
Return on Invested Capital (Normalized) | 11.23% | 0.33% | −54.02% |
Return on Assets
145020
085660
052020
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Bybmllshj | Pxzcz | $566.6 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Vdksndfw | Zkjhqkx | $102.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pzfpxxr | Drnyb | $98.3 Bil | |
MRNA
| Moderna Inc | Fwfmnkbb | Bbtq | $42.7 Bil | |
ARGX
| argenx SE ADR | Nvwsfmgn | Rqxcz | $22.2 Bil | |
BNTX
| BioNTech SE ADR | Bpvdzck | Qczgx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ygxtrqzsd | Ktqhspb | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Shgfvrqnp | Lxmrsvk | $15.6 Bil | |
RPRX
| Royalty Pharma PLC Class A | Cnnyjjmlw | Dttnq | $12.7 Bil | |
INCY
| Incyte Corp | Fdbvqcdk | Wvvcdsb | $11.8 Bil |